Lifeboat Foundation

They’re so much like humans. Hopefully this doesn’t hurt them in the long term.

Farms in India have reached out to the authorities after repeatedly being attacked by opium-addicted parrots.

Farmers in Madhya Pradesh say their opium crops are being ruined by parrots who keep returning to raid their farms in an attempt to get high. The farmers have been guarding the fields day and night to protect their poppies, but the birds are willing to risk it all to get their beaks on the opium, which is being farmed for medical purposes.

Continue reading “Parrots Keep Attacking Poppy Farms To Get High On Opium” »

Cancer cells are incredibly adaptable, much like stem cells. Researchers from the University of Basel have discovered substances that artificially mature breast cancer cells of the very aggressive triple-negative subtype and transform them into a state that is similar to normal cells.

Cancer occurs when cells grow uncontrollably and spread to other organs. Cancer cells are quite different from normal ones. Cancer cells are known for their remarkable adaptability to varied settings in the body as well as drug treatments. They resemble stem cells or cells at an early stage of development in this regard.

The prospect of artificially maturing (or, more accurately, differentiating) breast cancer cells as a strategy to transform them into a more normal kind of cell has been explored by researchers at the University of Basel and the University Hospital Basel.

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

TruDiagnostic Discount Link (Epigenetic Testing)
CONQUERAGING!
https://bit.ly/3Rken0n.

Continue reading “Bacteria From An Olympic Weightlifter Improves Muscle Mass And Physical Function (In Mice)” »

Elon Musk’s Neuralink is under federal investigation for potential animal-welfare violations after staff complaints about rushed animal testing. Ana Kasparian discusses on The Young Turks. Watch TYT LIVE on weekdays 6–8 pm ET. http://youtube.com/theyoungturks/live.

“Elon Musk’s Neuralink, a medical device company, is under federal investigation for potential animal-welfare violations amid internal staff complaints that its animal testing is being rushed, causing needless suffering and deaths, according to documents reviewed by Reuters and sources familiar with the investigation and company operations.

Continue reading “Neuralink NIGHTMARE: Elon’s Brain Chip Trials Are A Total Horror Show” »

If you’re expecting monoclonal antibody treatments to save you from getting more severe outcomes like death should you get Covid-19, it may be time to rethink that strategy. A letter published in The Lancet Infectious Diseases journal on November 18 detailed how many of the currently spreading Omicron subvariants, namely the BA.4.6, BA.2.75.2, and BJ.1 ones, appear to be resistant to most available monoclonal antibody treatments. And the BQ.1.1 Omicron subvariant, which has become one of the two dominant versions of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the U.S., seems resistant to all of the available monoclonal antibody treatments. Yes, all of them, as in every single one.

BQ certainly doesn’t stand for “be quiet,” as the BQ.1.1 subvariant is now causing a commotion, being responsible for an estimated 24.2% of all new reported Covid-19 cases over the past week while the not-too-different BQ.1 subvariant has been the culprit behind 25.5% of them, according to the Centers for Disease Control and Prevention (CDC). If you do the math, that means that these two Omicron subvariants are now comprising over half of all reported Covid-19 cases, meaning that they have overtaken the BA.5 as the “alpha-dog” of SARS-CoV-2 versions. Therefore, you can probably no longer rely on any type of monoclonal antibody should you get Covid-19. That’s certainly bad news for anyone not able to get enough protection from Covid-19 vaccination such as those who have very weak immune systems.

You know that 1997 Backstreet Boys song that goes “everybody, yeah?” Well, looks like the latest 2022 Covid-19 coronavirus Omicron subvariants have been going, “antibody, no-oh.” So much for the argument that other Covid-19 precautions are not needed because monoclonal antibodies are available. Even back in 2020 and 2021 when monoclonal antibody treatments seemed to work against the then-circulating previous versions of the virus, such an argument held water about as well as a Brillo pad thong since relying on any single Covid-19 precaution or treatment has always been a foolhardy approach. Doing so was akin to telling someone, “since you have underwear on, why do you need pants or a skirt or a kilt?” Ever since the start of the pandemic, real pandemic experts have continued to advocate for more of a “Swiss cheese” approach that entails always layering on different Covid-19 interventions simultaneously because each single intervention has its holes.

😗

BOSTON — Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is designed in such a way that natural selection to maintain infectiousness of the virus should also maintain the drug’s activity against future variants.

The investigational drug, described in a report published today in Science Advances, is not an antibody, but a related molecule known as an ACE2 receptor decoy. Unlike antibodies, the ACE2 decoy is far more difficult for the SARS-CoV-2 virus to evade because mutations in the virus that would enable it to avoid the drug would also reduce the virus’s ability to infect cells. The Dana-Farber scientists found a way to make this type of drug neutralize coronaviruses more potently in animals infected with COVID-19 and to make it safe to give to patients.

Continue reading “New receptor ‘decoy’ drug neutralizes COVID-19 virus and its variants” »

A recent study from Tokyo Medical and Dental University found that melatonin and two of its metabolites help memories stick around in the brain and can shield mice, and potentially people, from cognitive decline. One of the easiest ways to test memory in mice is to rely on their natural tendency to examine unfamiliar objects.

Summary: Researchers have identified a protein that could be leveraged to help microglia in the brain stave off Alzheimer’s and other neurodegenerative diseases.

Source: The Conversation.

Many neurodegenerative diseases, or conditions that result from the loss of function or death of brain cells, remain largely untreatable. Most available treatments target just one of the multiple processes that can lead to neurodegeneration, which may not be effective in completely addressing disease symptoms or progress, if at all.

The drug, midazolam, is often used before surgery to make a patient feel more relaxed. According to a new study, it is associated with an increased risk of heart damage when surgeries are performed at night.

According to a study conducted by researchers at the University of Colorado Anschutz Medical Campus, a popular drug that makes patients sleepy and less anxious before surgery is associated with an increased risk of heart damage when surgeries are performed at night.

The results provide further proof that a drug’s effectiveness might vary depending on the time it is administered.